P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS

• P. Cramer,
• M. Fürstenau,
• A. Giza,
• S. Robrecht,
• E. Tausch,
• C. Schneider,
• C.-M. Wendtner,
• M. Hoechstetter,
• J. Schetelig,
• S. Böttcher,
• P. Dreger,
• A.-M. Fink,
• P. Langerbeins,
• O. Al-Sawaf,
• K. Fischer,
• S. Stilgenbauer,
• B. Eichhorst,
• M. Hallek

Affiliations

P. Cramer

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

M. Fürstenau

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

A. Giza

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

S. Robrecht

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

E. Tausch

2 Department III of Internal Medicine, University Hospital Ulm, Ulm

C. Schneider

2 Department III of Internal Medicine, University Hospital Ulm, Ulm

C.-M. Wendtner

3 Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich

M. Hoechstetter

3 Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich

J. Schetelig

4 Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden

S. Böttcher

5 Department III of Internal Medicine, University Hospital Rostock, Rostock

P. Dreger

6 Department V of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany

A.-M. Fink

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

P. Langerbeins

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

O. Al-Sawaf

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

K. Fischer

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

S. Stilgenbauer

2 Department III of Internal Medicine, University Hospital Ulm, Ulm

B. Eichhorst

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne

M. Hallek

1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne